OverviewChartNewsTraderScreen

BVT Aktienanleihe AMD 28.06.2024/  DE000VU8J590  /

EUWAX
5/10/2024  8:53:12 AM Chg.- Bid8:03:03 AM Ask8:03:03 AM Underlying Strike price Expiration date Option type
101.27EUR - 101.24
Bid Size: 50,000		 101.34
Ask Size: 50,000		 Advanced Micro Devic... 120.00 USD 6/28/2024 Call
GlobeNewswire 5/9 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 5/9 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire 5/9 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 5/8 Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire 5/8 Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire 5/8 AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire 5/8 Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire 5/8 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire 5/7 Ocular Therapeutix™ Reports First Quarter 2024 Results
GlobeNewswire 5/7 Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire 5/7 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GlobeNewswire 5/7 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 5/6 Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire 5/6 Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire 5/6 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire 5/6 Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
GlobeNewswire 5/6 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...
GlobeNewswire 5/3 Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
GlobeNewswire 5/3 YieldMax™ ETFs Announces Monthly Distributions on CONY (109.51%), MSTY (103.22%), NFLY (67.74%), SQY...
GlobeNewswire 5/2 Outlook Therapeutics® to Present at the Retina World Congress 2024
GlobeNewswire 5/2 Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology...
GlobeNewswire 5/2 YieldMax™ Launches Short TSLA Option Income Strategy ETF CRSH
GlobeNewswire 5/1 Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 A...
GlobeNewswire 5/1 Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Mark...
TeleTrader 5/1 AI-related stocks plunge, Super Micro leads with 17% decline